UBS Group’s BiondVax Pharmaceuticals Ltd. BVXVW Stock Holding History

UBS Group’s Portfolio BVXVW Stock Details BVXVW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,179	Closed	-$3K	–	8749
2019 Q4	$3K	Sell	1,179 -24	-2%	-$32	﹤0.01%	7800
2019 Q3	$1K	Hold	1,203	–	–	﹤0.01%	7915
2019 Q2	$1K	Hold	1,203	–	–	﹤0.01%	7788
2019 Q1	$0	Hold	1,203	–	–	﹤0.01%	8453
2018 Q4	$1K	Sell	1,203 -100	-8%	-$96	﹤0.01%	7952
2018 Q3	$2K	Hold	1,303	–	–	﹤0.01%	7788
2018 Q2	$2K	Buy	+1,303	New	+$1.7K	﹤0.01%	7772
2017 Q1	–	Sell	-2,001	Closed	-$1K	–	8172
2016 Q4	$1K	Sell	2,001 -199	-9%	-$80	﹤0.01%	7676
2016 Q3	$1K	Buy	+2,200	New	+$1.28K	﹤0.01%	7567

Other funds holding BVXVW

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

FWM

Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

UBS Group's BVXVW Position: Q1 2020 in Review

UBS Group sold out of BiondVax Pharmaceuticals Ltd. (BVXVW) in Q1 2020, closing a stake of 1,179 shares — an estimated $3K sold.

UBS Group first reported a position in BVXVW in Q3 2016 and held it in 9 quarters. The position peaked at $3K in Q4 2019. 2 funds tracked by Wall St. Rank hold BVXVW as of Q1 2020.

UBS Group reported no remaining BiondVax Pharmaceuticals Ltd. position as of Q1 2020 after selling out during the quarter.
UBS Group sold 1,179 BiondVax Pharmaceuticals Ltd. shares in Q1 2020, an estimated $3K.
UBS Group first reported a position in BiondVax Pharmaceuticals Ltd. in Q3 2016 and held it in 9 quarters.
UBS Group's BiondVax Pharmaceuticals Ltd. position peaked at $3K in Q4 2019.
2 funds tracked by Wall St. Rank held BiondVax Pharmaceuticals Ltd. as of Q1 2020.

Based on UBS Group's 13F filing for Q1 2020, filed 1 May 2020.